[go: up one dir, main page]

BRPI0517401A - tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores - Google Patents

tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores

Info

Publication number
BRPI0517401A
BRPI0517401A BRPI0517401-5A BRPI0517401A BRPI0517401A BR PI0517401 A BRPI0517401 A BR PI0517401A BR PI0517401 A BRPI0517401 A BR PI0517401A BR PI0517401 A BRPI0517401 A BR PI0517401A
Authority
BR
Brazil
Prior art keywords
infections
prevention
treatment
immunomodulatory compounds
viral haemorrhagic
Prior art date
Application number
BRPI0517401-5A
Other languages
English (en)
Inventor
Eric C Mossel
Cynthia W Thuthill
Alfred R Rudolph
Clarence James Peters
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of BRPI0517401A publication Critical patent/BRPI0517401A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO OU PREVENçãO DE INFECçõES HEMORRáGICAS VIRAIS COM COMPOSTOS IMUNOMODULADORES. Um composta imunomodulatório é administrado a um paciente com, ou em risco de uma infecção viral hemorrágica.
BRPI0517401-5A 2004-10-27 2005-10-27 tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores BRPI0517401A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62202204P 2004-10-27 2004-10-27
PCT/US2005/038834 WO2006047702A2 (en) 2004-10-27 2005-10-27 Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

Publications (1)

Publication Number Publication Date
BRPI0517401A true BRPI0517401A (pt) 2008-10-14

Family

ID=36228480

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517401-5A BRPI0517401A (pt) 2004-10-27 2005-10-27 tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores

Country Status (19)

Country Link
US (1) US8193152B2 (pt)
EP (1) EP1814566B1 (pt)
JP (1) JP4874985B2 (pt)
KR (1) KR20070070202A (pt)
CN (1) CN101048171B (pt)
AT (1) ATE475426T1 (pt)
AU (1) AU2005299609A1 (pt)
BR (1) BRPI0517401A (pt)
CA (1) CA2585457A1 (pt)
DE (1) DE602005022612D1 (pt)
EA (1) EA012342B1 (pt)
ES (1) ES2350087T3 (pt)
IL (1) IL182710A (pt)
MX (1) MX2007005092A (pt)
NO (1) NO20072498L (pt)
NZ (1) NZ555322A (pt)
SG (1) SG163601A1 (pt)
UA (1) UA92727C2 (pt)
WO (1) WO2006047702A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
AU2008216799A1 (en) 2007-02-13 2008-08-21 Sciclone Pharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
MXPA06013050A (es) 2004-05-14 2007-03-28 Sciclone Pharmaceuticals Inc Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
UA12948U (en) 2005-07-11 2006-03-15 Inst Of Veterinary Medicine Uk Associated inactivated concentrated serdosan vaccine against colibacteriosis, edematous disease, pasteurellosis, salmonellosis, and anaerobic enterotoxicemia of pigs

Also Published As

Publication number Publication date
EA012342B1 (ru) 2009-10-30
CN101048171B (zh) 2011-02-09
MX2007005092A (es) 2007-07-04
EP1814566A2 (en) 2007-08-08
WO2006047702A3 (en) 2006-07-20
JP4874985B2 (ja) 2012-02-15
SG163601A1 (en) 2010-08-30
KR20070070202A (ko) 2007-07-03
DE602005022612D1 (de) 2010-09-09
CA2585457A1 (en) 2006-05-04
EP1814566B1 (en) 2010-07-28
NZ555322A (en) 2009-02-28
JP2008518031A (ja) 2008-05-29
WO2006047702A2 (en) 2006-05-04
CN101048171A (zh) 2007-10-03
AU2005299609A1 (en) 2006-05-04
EP1814566A4 (en) 2008-05-07
ATE475426T1 (de) 2010-08-15
IL182710A (en) 2012-04-30
EA200700878A1 (ru) 2007-10-26
US8193152B2 (en) 2012-06-05
ES2350087T3 (es) 2011-01-18
UA92727C2 (ru) 2010-12-10
IL182710A0 (en) 2007-07-24
US20090143313A1 (en) 2009-06-04
NO20072498L (no) 2007-05-15

Similar Documents

Publication Publication Date Title
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
ATE512976T1 (de) Hemmer des hepatitis-c-virus
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
TW200733953A (en) Materials and methods for treating viral infections
GB0612423D0 (en) Therapeutic agents
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
GEP20146134B (en) Inhibitors of hepatitis c virus replication
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
MY186986A (en) Compositions and methods of use of phorbol esters
RU2015114543A (ru) Способы лечения гепатита с
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
RU2010153688A (ru) Режим дозирования телапревира
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
NO20065518L (no) Behandling eller forebyggelse av respiratoriske virusinfeksjoner med immunmodulerende forbindelser.
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
BRPI0517401A (pt) tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores
WO2009023356A3 (en) Materials and methods for treating influenza infections
WO2004052905A3 (en) Antiviral nucleoside derivatives
DK1350510T3 (da) Anvendelse af et middelt til undertrykkelse af infektion og proliferation af humant immundefektvirus
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SCICLONE PHARMACEUTICALS, INC. (US) , THE BOARD OF

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: SCICLONE PHARMACEUTICALS, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.